NetworkNewsBreaks – PreveCeutical Medical Inc. (
Post# of 77
PreveCeutical Medical (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) aims to be a leader in the preventive health sciences and provide revolutionary options for preventive and curative therapies utilizing organic products. An article discussing the company reads: “PreveCeutical currently has five research and development programs, including dual gene therapy for curative and prevention therapies for diabetes and obesity. The World Health Organization (WHO) states that some 425 million people around the world are living with diabetes, and that number is projected to rise to 629 million by 2045. Treating diabetes is a costly matter, both economically and in terms of physical harm done to the individual. Healthcare expenditures to treat diabetes totaled $727 billion in 2017, according to Statista (http://nnw.fm/7Q6w1).”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer